Insmed, Inc. $INSM Shares Sold by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lessened its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 25.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,853 shares of the biopharmaceutical company’s stock after selling 5,521 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Insmed were worth $2,283,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Spire Wealth Management boosted its stake in shares of Insmed by 11.5% during the 3rd quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 80 shares during the last quarter. MassMutual Private Wealth & Trust FSB raised its position in shares of Insmed by 59.6% in the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 81 shares during the last quarter. Moody Aldrich Partners LLC lifted its stake in shares of Insmed by 2.4% during the third quarter. Moody Aldrich Partners LLC now owns 5,551 shares of the biopharmaceutical company’s stock valued at $799,000 after buying an additional 132 shares during the period. AlphaQuest LLC boosted its position in Insmed by 109.5% during the third quarter. AlphaQuest LLC now owns 287 shares of the biopharmaceutical company’s stock worth $41,000 after acquiring an additional 150 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. boosted its position in Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after acquiring an additional 151 shares during the last quarter.

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Zacks expects Insmed to beat upcoming earnings, which could support the stock if results and guidance meet those expectations. Insmed (INSM) Expected to Beat Earnings Estimates
• Positive Sentiment: Brokerage coverage remains constructive — the consensus rating is around “Buy” with several firms assigning strong-buy/outperform calls and an average price target well above current levels, which supports medium-term upside. Insmed Given Average Rating of “Buy” by Brokerages
• Neutral Sentiment: Short-interest reports in the feeds show anomalous/zero values and NaN changes — data appears unreliable. This reduces clarity on whether rising short interest is a meaningful driver today. (Treat short-interest signals with caution.)
• Neutral Sentiment: Trading volume is modestly above average, indicating elevated attention but not an extreme flow that would by itself explain a sustained move.
• Negative Sentiment: CEO William Lewis disclosed the sale of 13,396 shares (and has sold several tranches in recent weeks). High-profile insider selling is being read as a bearish signal by some investors and likely contributed to downward pressure. Insmed CEO William Lewis Sells 13,396 Shares
• Negative Sentiment: Coverage flagged “possible bearish signals” tied to insider disposals, amplifying investor concern and short-term selling pressure. Possible Bearish Signals With Insmed Insiders Disposing Stock

Insider Buying and Selling

In related news, CEO William Lewis sold 19,215 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the transaction, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at approximately $51,864,579. The trade was a 5.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the business’s stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the transaction, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. The trade was a 67.64% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 248,253 shares of company stock worth $44,322,342. Company insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

INSM has been the topic of a number of recent analyst reports. Truist Financial set a $205.00 price target on Insmed in a research note on Monday, January 12th. Citigroup reiterated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research note on Thursday, January 22nd. Cantor Fitzgerald upped their price objective on shares of Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Leerink Partners reiterated an “outperform” rating on shares of Insmed in a report on Thursday, December 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Insmed has a consensus rating of “Buy” and a consensus target price of $204.24.

Insmed Stock Performance

Shares of NASDAQ:INSM opened at $146.17 on Friday. The firm has a market capitalization of $31.17 billion, a PE ratio of -23.61 and a beta of 1.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. The business has a 50-day moving average of $170.16 and a two-hundred day moving average of $161.17. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.